Browse study websites

Discover. Prevent. Cure.

Menu Fundraise Donate

    Recommended pages

      Do you mean

        Sarcoma Translational Research

        We think all kids with Sarcoma should be able to lead happy, healthy lives! To achieve this, we aim to discover and develop safer and more effective treatments by doing inventive and rigorous research. We focus on addressing high relapse rates using a combination of unique pre-clinical models, patient samples and systems immunology.

        Sarcomas are a heterogenous group of cancers of the bone, muscle, or connective tissue.

        About 15% of cancers in children and adolescents are sarcomas whereas only 1% of cancers in adults are sarcomas. Although many sarcomas can be cured with standard therapy, the relatively high incidence of the disease in younger people and the frequency of recurrence makes the development of more effective therapies a high priority.

        The Sarcoma Group aims to identify new treatments for young people with sarcoma. In particular, we are developing immunotherapy approaches that can be applied during surgery in order to prevent local relapse and metastasis.

        Today Tonight

        The new sarcoma research team

        The new sarcoma research team

        Related Links

        Telethon Kids

        Cancer Centre

        Visit the site

        Team

        Leader

        Associate Professor W. Joost Lesterhuis

        Program Head, Cancer / Chronic and Severe Diseases RFA Deputy Head / Simon Lee Fellow

        Email me

        Members

        Ben Wylie

        BSc, PhD

        Postdoctoral Researcher, Sarcoma Translational Research

        Email me LinkedIn

        Rachael Zemek
        Postdoctoral Researcher

        Postdoctoral Researcher

        Tao Wang
        Research Officer

        Research Officer

        Lizeth Orozco
        Research Officer

        Research Officer

        Dat Nguyen
        Research Assistant

        Research Assistant

        Francois Rwandamuriye
        PhD Student (Sock it to Sarcoma Scholarship)

        PhD Student (Sock it to Sarcoma Scholarship)

        Breana Vitali
        PhD Student (Sock it to Sarcoma Scholarship)

        PhD Student (Sock it to Sarcoma Scholarship)

        Xueting Ye
        PhD Student

        PhD Student

        Tilly Gorce
        Honours Student

        Honours Student

        Eloise Delaney
        Honours Student

        Honours Student

        Related teams

        Sarcoma Translational Research projects

        The interplay between sarcoma and surgery-induced wound healing

        Learn more

        Local immunotherapy for sarcoma

        Learn more

        Reports and Findings

        Show all
        May 2022

        Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations

        Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA‐4) and the programmed cell death protein 1/ligand 1 (PD-1/PD-L1) are now a treatment option for multiple cancer types. However, as a monotherapy, objective responses only occur in a minority of patients. Chemotherapy is widely used in combination with immune checkpoint blockade (ICB). Although a variety of isolated immunostimulatory effects have been reported for several classes of chemotherapeutics, it is unclear which chemotherapeutics provide the most benefit when combined with ICB.

        Children's Cancers Published research Subsite: Cancer Sarcoma Translational Research
        Read more
        April 2022

        Non-severe burn injury increases cancer incidence in mice and has long-term impacts on the activation and function of T cells

        Recent evidence suggests that burn patients are at increased risk of hospital admission for infection, mental health conditions, cardiovascular disease and cancer for many years after discharge for the burn injury itself.

        Published research Sarcoma Translational Research Translational Genetics
        Read more
        April 2022

        Adherence to Oral Targeted Anti-Lung Cancer Therapy: A Qualitative Interview Study

        Oral targeted antineoplastic drugs (OTADs) are becoming more and more acceptable for lung cancer treatment due to their advantages such as the convenience of administration and milder side effects. However, medication adherence represents a major issue for prolonged OTAD treatment.

        Published research Sarcoma Translational Research
        Read more
        May 2022

        The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy

        High medication literacy is the basis of rational medication application and is essential for the management of severe adverse drug reactions. The objective of the present study was to assess the level of medication literacy and determine the association between medication literacy and skin adverse drug reactions in non-small-cell lung cancer (NSCLC) patients undergoing targeted epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy.

        Children's Cancers Published research Sarcoma Translational Research
        Read more